Cancer vaccines consist of one or more antigenic components, including live-attenuated or killed viral or bacterial particles, proteins, polysaccharides, polynucleotides, and particle conjugates. Additionally, other excipients like adjuvants may be present. Not only the chemical and structural integrity of various components must be maintained, but the immunogenicity must be ensured. Thus, the complexity of vaccines creates a unique challenge for characterization.
As a first-class service producer, Creative Biolabs describes a wide range of analytical technologies for diverse vaccine modalities. These include cancer vaccine identification of physicochemical properties, the purification, and potency testing, and the application of both classical and modern bio-analytical tools. With the help of us, the candidate of cancer vaccines can meet and exceed the GMP requirement quickly and smoothly.
Today, cancer vaccine is developed either as a prophylactic agent to prevent future infection or as a therapeutic treatment. Here, our vaccine development teams perform a comprehensive suite of methods to evaluate the components of cancer vaccines, including protein (glycoprotein, lipoprotein, etc.), lipid, carbohydrate, and lipopolysaccharide. Specifically, we offer total quality assurance expertise to assist clients’ products up to quality with safety and regulatory standards.
Biological Analytical Assays
Physicochemical Analytical Technologies
Creative Biolabs’ teams possess technical expertise in GMP vaccine analytical development and have gained a great reputation in the vaccine industry. We can offer specialized contract services for almost any cancer vaccines to obtain their identity, purity, efficacy, and quantity and provide GMP-compliant process development services.
Furthermore, there is another support for cancer vaccine developments and manufacture studies for stable, efficient, and potent products. If you’re interested in related services, please don’t hesitate to contact us.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE